 |
 |
 |
 |
 |
Subject: Dystonia: Rating Scale, Cannabinoid Stimulation (AAN 2001) Date: 5/23/2001 E-MOVE reports from the 53rd Annual Meeting of the American Academy of Neurology in Philadelphia May 5-11, 2001. Poster and Platform session numbers refer to abstracts published in Neurology 2001;56 (Supplement 3).1. S49.008 Rating Scales for dystonia: A multicenter assessment of three dystonia rating scales: The Unified Dystonia Rating Scale (UDRS), the Burke-Fahn-Marsden (BFM) and the Global Dystonia Rating Scale (GDS) CL Comella, Dystonia Study Group The Global Dystonia Rating Scale is a simple and reliable tool for assessment of dystonia in a clinical setting, according to this study. One hundred patients with various types of dystonia were assessed via videotape by dystonia specialists using each of the three scales. Total scores and individual body area scores showed high interrater agreement on all scales, with lowest agreement for eyes and face, and highest for the extremities. The GDS, which rates dystonia in 14 body areas from 0-10, was rated by specialists as easiest to use, which "suggests that it may be the most promising scale to be developed further as a clinical tool." 2. P02.097 A randomized, double-blind, placebo-controlled trial to assess the potential of cannabinoid receptor stimulation in the treatment of dystonia SH Fox, M Kellett, P Moore, AR Crossman, JR Brotchie Fifteen patients with generalized or segmental dystonia received either placebo or a single dose of 0.03 mg/kg nabilone followed by a two-week washout and crossover to the other arm. Dystonia was assessed three hours after dosing. No significant effect of treatment was seen. The authors note the dose used is similar to that employed as an anti-emetic in chemotherapy. E-MOVE Editor: Richard Robinson, NASW, WE MOVE
|
|
| All contents copyright © WE MOVE 2010. This page last modified 2/25/2009. | |